7-[5-[3-(4-hydroxypiperidin-1-yl)propoxy]-1H-indol-2-yl]-2,3-dihydroisoindol-1-one
C24H27N3O3 — CID 44579918
Data last refreshed: (MolForge compound catalog, from PubChem)
About 7-[5-[3-(4-hydroxypiperidin-1-yl)propoxy]-1H-indol-2-yl]-2,3-dihydroisoindol-1-one
7-[5-[3-(4-hydroxypiperidin-1-yl)propoxy]-1H-indol-2-yl]-2,3-dihydroisoindol-1-one (PubChem CID 44579918) has the molecular formula C24H27N3O3 and a molecular weight of 405.50 g/mol. Its IUPAC name is 7-[5-[3-(4-hydroxypiperidin-1-yl)propoxy]-1H-indol-2-yl]-2,3-dihydroisoindol-1-one.
Molecular Properties
| Compound Name | 7-[5-[3-(4-hydroxypiperidin-1-yl)propoxy]-1H-indol-2-yl]-2,3-dihydroisoindol-1-one |
|---|---|
| PubChem CID | 44579918 |
| Molecular Formula | C24H27N3O3 |
| Molecular Weight | 405.50 g/mol |
| Exact Mass | 405.21 |
| IUPAC Name | 7-[5-[3-(4-hydroxypiperidin-1-yl)propoxy]-1H-indol-2-yl]-2,3-dihydroisoindol-1-one |
| SMILES | O=C1NCc2cccc(-c3cc4cc(OCCCN5CCC(O)CC5)ccc4[nH]3)c21 |
| InChI | InChI=1S/C24H27N3O3/c28-18-7-10-27(11-8-18)9-2-12-30-19-5-6-21-17(13-19)14-22(26-21)20-4-1-3-16-15-25-24(29)23(16)20/h1,3-6,13-14,18,26,28H,2,7-12,15H2,(H,25,29) |
| InChIKey | XFVLOFSAMRZDHH-UHFFFAOYSA-N |
| XLogP | 3.30 |
| TPSA | 77.59 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 405.50 |
| LogP ≤ 5 | 3.30 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 44579918 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.